ESPR
NASDAQEsperion Therapeutics Inc.
Price$3.15-0.00 (-0.16%)
01:30 PM03:45 PM
News · 26 weeks53+11%
2025-12-142026-06-07
Mix3590d
- Other13(37%)
- Insider11(31%)
- SEC Filings8(23%)
- Earnings2(6%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Esperion Therapeutics Inc.SCHEDULE 13G - Esperion Therapeutics, Inc. (0001434868) (Subject)
- SECSEC Form DEFM14A filed by Esperion Therapeutics Inc.DEFM14A - Esperion Therapeutics, Inc. (0001434868) (Filer)
- INSIDERDirector Thompson John Craig was granted 79,873 shares (SEC Form 4)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERDirector Shepard Jay was granted 79,873 shares, increasing direct ownership by 94% to 164,472 units (SEC Form 4)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERDirector Hoffman Robert E. was granted 79,873 shares, increasing direct ownership by 1,513% to 85,153 units (SEC Form 4)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERDirector Fischer Seth H. Z. was granted 79,873 shares, increasing direct ownership by 131% to 141,023 units (SEC Form 4)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERDirector Carroll J Martin was granted 79,873 shares, increasing direct ownership by 82% to 177,523 units (SEC Form 4)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- SECEsperion Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form PREM14A filed by Esperion Therapeutics Inc.PREM14A - Esperion Therapeutics, Inc. (0001434868) (Filer)
- PREsperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-C in Statin Intolerant Adults – ANN ARBOR, Mich., May 26, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the presentation of results from a Phase 2 study of bempedoic acid in children, along with an additional post hoc analysis from CLEAR Outcomes describing patient traits associated an enhanced LDL-C lowering with bempedoic acid. These data were presented as moderated Science at a Glance sessions at the European Atherosclerosis Society (EAS) Congress 2026 taking place on Ma
- PREsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each RSU will vest and become exercisable as to 25 percent of the shares on
- PREsperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2 Study Demonstrated Bempedoic Acid Treatment Reduced LDL-C in Children with Heterozygous Familial Hypercholesterolemia (HeFH) Congruent with Reductions in Adult Exposures – – New Analyses from CLEAR Outcomes Trial Identified Factors Associated With Enhanced LDL-C Reductions in Adult Patients – ANN ARBOR, Mich., May 13, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two new abstracts and three encore abstracts have been accepted for presentation at the European Atherosclerosi
- SECSEC Form 10-Q filed by Esperion Therapeutics Inc.10-Q - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form DEFA14A filed by Esperion Therapeutics Inc.DEFA14A - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form DEFA14A filed by Esperion Therapeutics Inc.DEFA14A - Esperion Therapeutics, Inc. (0001434868) (Filer)
- ANALYSTEsperion Therapeutics downgraded by H.C. WainwrightH.C. Wainwright downgraded Esperion Therapeutics from Buy to Neutral
- PREsperion to be Acquired by ARCHIMEDEsperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of up to approximately $1.1 billion ANN ARBOR, Mich., May 01, 2026 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ:ESPR) ("Esperion," or the "Company"), a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies, and ARCHIMED ("ARCHIMED"), a leading investment firm focused exclusively on healthcare industries, today announced that they have entered into a definitive agreement under which funds managed by ARCHIM
- PREsperion to Report First Quarter 2026 Financial Results on May 7ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. About Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical c
- SECSEC Form SCHEDULE 13G filed by Esperion Therapeutics Inc.SCHEDULE 13G - Esperion Therapeutics, Inc. (0001434868) (Subject)
- SECSEC Form DEFA14A filed by Esperion Therapeutics Inc.DEFA14A - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form DEF 14A filed by Esperion Therapeutics Inc.DEF 14A - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECEsperion Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)
- PRAthyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis TherapeuticsAthyrium Funds purchased a portion of the royalties payable to Esperion on Japan net sales of Otsuka's bempedoic acid products, together with related milestone payments, subject to a cap, for total consideration of $50 millionAthyrium Funds to receive tiered royalties ranging from 12% to 33%, as well as milestone payments, until receiving aggregate payments equal to 2.0x their investment, after which all rights revert to EsperionFinancing supports Esperion's acquisition of Corstasis Therapeutics Inc., which developed and is commercializing Enbumyst™, the first FDA-approved intranasal loop diuretic for treatment of edema associated with cardiovascular and hepatic and renal disease NEW YORK a
- PREsperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth – ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) (the Company) today announced the closing of its acquisition of Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular and hepatic and renal disease. "The closing of this acquisition marks an important milestone in advancing our Vision 2040 and strengthens our commitm
- PREsperion to Participate in 25th Annual Needham Virtual Healthcare ConferenceANN ARBOR, Mich., March 31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the webcasted 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therap
ESPR FAQ
7 questionsWhat does Esperion Therapeutics Inc. do?
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9...Where does ESPR stock trade?
Esperion Therapeutics Inc. (ESPR) is listed on NASDAQ.What sector and industry is ESPR in?
Esperion Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Esperion Therapeutics Inc. go public?
Esperion Therapeutics Inc. (ESPR) completed its IPO in 2013.What are analysts saying about ESPR?
Esperion Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-05-01. Recent price targets range from $250.00 to $900.00.What companies are similar to ESPR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ESPR side-by-side with any of them on Quantisnow.How can I track ESPR on Quantisnow?
Quantisnow aggregates Esperion Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ESPR to receive live email and push alerts on every new disclosure.